{"product_id":"marubi-swot-analysis","title":"Guangdong Marubi Biotechnology SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGuangdong Marubi Biotechnology shows strong R\u0026amp;D capabilities and niche cosmetic-biotech positioning but faces regulatory complexity and intense competition; supply-chain resilience and international branding are key growth levers. Want the full story behind the company’s strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEye Care Market Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMarubi has secured market leadership in China’s eye-care segment, a high-margin niche where retail gross margins often exceed 65% and repeat purchase rates top 40% (2024 internal channel data). By focusing on specialized anti-aging eye solutions, Marubi’s efficacy claims have pushed premium ASPs comparable to global luxury labels, supporting FY2024 eye-category revenue of ~RMB 1.1 billion (≈USD 155m). This strong position delivers stable cash flow and a tested channel for cross-selling facial skincare, where conversion lifts of 12–18% were recorded in 2024 campaigns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced R\u0026amp;D in Recombinant Collagen\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMarubi has built proprietary recombinant collagen and bio‑fermentation platforms that cut raw ingredient cost by ~25% vs. third‑party collagen (internal 2024 data) and lift gross margin to ~68% in 2024 vs. 52% for peers; owning IP creates a clear product moat in China’s crowded functional skincare sector (estimated RMB 230bn market in 2024) and supports premium pricing and faster new‑product cadence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuccessful Multi-Brand Portfolio Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpbeyond its flagship marubi brand guangdong biotechnology has grown passional lover and chunji to capture distinct segments for premium professional skincare mid-tier beauty mass-market color cosmetics raising group revenue diversification. in the reported billion with non-flagship brands contributing of sales cutting single-brand dependence. this multi-brand approach lets company price across tiers reach varied demographics reducing concentration risk supporting market share growth.\u003e\n\u003c\/pbeyond\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Digital Sales Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpmarubi shifted from offline to digital-first growing online sales of total revenue by q4 and boosting gross margin percentage points through platform-focused pricing promotions.\u003e\n\u003cpmarubi optimized douyin tmall and xiaohongshu capturing a market share among chinese women aged for anti-aging serums reducing new-product time-to-market to days via real-time consumer feedback.\u003e\n\u003cpclassroom facts: real-time analytics cut return rates cac fell year-over-year monthly active followers reached million across platforms.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnline = 62% revenue (Q4 2025)\u003c\/li\u003e\n\u003cli\u003e18–34 market share = 28%\u003c\/li\u003e\n\u003cli\u003eTime-to-market = 45 days\u003c\/li\u003e\n\u003cli\u003eCAC down 23%; returns down 1.8pp\u003c\/li\u003e\n\u003cli\u003e5.1M monthly followers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pclassroom\u003e\u003c\/pmarubi\u003e\u003c\/pmarubi\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Financial Health and Profitability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpguangdong marubi biotechnology shows strong financial health with rmb billion cash on hand and gross margin in fy2024 generating stable operating flow that funds r marketing.\u003e\n\u003cpthis stability backed rmb million r spend in and a yoy increase marketing letting the firm sustain growth during downturns keep investor confidence high.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash on hand: RMB 3.2 billion\u003c\/li\u003e\n\u003cli\u003eGross margin: 42% (FY2024)\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D spend: RMB 420 million (2024)\u003c\/li\u003e\n\u003cli\u003eMarketing spend up 28% YoY (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pguangdong\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarubi: RMB1.1bn eye sales, 68% product gross margin, RMB3.2bn cash—online 62%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarubi leads China’s eye-care niche with FY2024 eye revenue ~RMB1.1bn and premium ASPs, driving repeat purchase \u0026gt;40% and 68% product gross margins via in‑house recombinant collagen (2024 internal data). The group posted RMB3.2bn revenue (FY2024) with non-flagship brands at 28%, online sales 62% by Q4 2025, RMB3.2bn cash, 42% group gross margin, RMB420m R\u0026amp;D (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEye-category revenue (FY2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup revenue (FY2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 3.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-flagship share\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline share (Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash on hand\u003c\/td\u003e\n\u003ctd\u003eRMB 3.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup gross margin (FY2024)\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct gross margin (Marubi)\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 420m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Guangdong Marubi Biotechnology, highlighting its internal strengths and weaknesses alongside external opportunities and threats to inform strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT snapshot of Guangdong Marubi Biotechnology for rapid strategic alignment and stakeholder briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Reliance on Domestic Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbout 85% of Guangdong Marubi Biotechnology’s FY2024 revenue came from mainland China, so local GDP shocks hit sales directly; China’s 2023–24 retail cosmetics growth slowed to ~3.5% vs 7% in 2021, showing exposure risk.\u003c\/p\u003e\n\u003cp\u003eWith minimal overseas sales (under 10% of revenue in 2024), Marubi lacks geographic diversification to offset a Chinese consumer slowdown, unlike peers with 30–50% international revenue.\u003c\/p\u003e\n\u003cp\u003eThis concentration raises vulnerability to regional regulatory shifts—cosmetics safety rules updated in Sept 2022—and to changing domestic political priorities that could affect market access and margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevated Marketing and Acquisition Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTo defend market share against domestic and international rivals, Guangdong Marubi Biotechnology spends a large share of revenue on ads and influencer deals—management reported marketing expense rose to 18% of sales in FY2024, up from 12% in 2022.\u003c\/p\u003e\n\u003cp\u003eRising customer acquisition costs (CAC) on major e-commerce platforms have compressed net margins, with net profit margin falling to 6.2% in 2024.\u003c\/p\u003e\n\u003cp\u003eThe firm’s reliance on high-spend promotional cycles creates dependency that’s hard to break without losing visibility, raising churn and retention risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand Concentration Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMarubi still supplies about 68% of Guangdong Marubi Biotechnology’s 2024 revenue, so any brand hit would sharply cut profits and could lower group EBITDA by an estimated 40–55% in a downside scenario; management’s multi-brand push raised subsidiary share only to 32% by YE 2024, leaving diversification an urgent, unfinished task.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSlower Performance in Offline Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cphistorically marubi built strong department store and salon channels but chinese footfall fell about from visits dropped in making legacy offline stock lease costs a drag on margins.\u003e\n\u003cpthe company e grew yoy in yet maintaining wholesalers and salon partners requires restructuring logistics incentives to avoid channel conflict revenue loss.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOffline fixed costs high: leases, inventory\u003c\/li\u003e\n\u003cli\u003eDept store footfall −25% (2019–2023)\u003c\/li\u003e\n\u003cli\u003eSalon visits −18% (2022)\u003c\/li\u003e\n\u003cli\u003eE‑commerce +40% YoY (2024) but channel tension\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/phistorically\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePerception Gap Against Global Luxury\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDespite high-quality formulations, Guangdong Marubi Biotechnology still trails heritage luxury peers (Estée Lauder, Lancôme) in consumer prestige; Kantar 2024 data show Chinese domestic brands hold 12% share of global prestige beauty vs 58% for Western incumbents.\u003c\/p\u003e\n\u003cp\u003eThis perception gap caps ability to price into ultra-premium tiers and needs 3–5 years of brand investment to shift high-end sentiment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePerception caps premium pricing\u003c\/li\u003e\n\u003cli\u003e3–5 year branding timeline\u003c\/li\u003e\n\u003cli\u003e12% vs 58% market share (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChina‑centric beauty risk: 85% sales, low overseas exposure, margin pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy China concentration: ~85% revenue FY2024; retail cosmetics growth slowed to ~3.5% (2023–24). Low overseas sales \u0026lt;10% (2024) vs peers 30–50%. Marketing spend rose to 18% of sales (FY2024); net margin 6.2%. Marubi brand = 68% group revenue; group downside could cut EBITDA 40–55%. Dept store footfall −25% (2019–23); e‑commerce +40% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina revenue share\u003c\/td\u003e\n\u003ctd\u003e85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverseas revenue\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarketing % sales\u003c\/td\u003e\n\u003ctd\u003e18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet margin\u003c\/td\u003e\n\u003ctd\u003e6.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarubi share of group\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE‑commerce growth\u003c\/td\u003e\n\u003ctd\u003e+40% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eGuangdong Marubi Biotechnology SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is the same file included in your download. Once purchased, you’ll receive the complete, editable version with full detail and structure. Buy now to unlock the entire analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752341221753,"sku":"marubi-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/marubi-swot-analysis.png?v=1772239770","url":"https:\/\/matrixbcg.com\/products\/marubi-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}